RxDoctor Payments Data

Tricia Lennox Thomas, MD

Ophthalmology · Willingboro, NJNPI 1760423826

Payments from drug & device makers

$1,390in general payments, 2019–2025

Across 48 payments — averaging $28.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$299
  • Tarsus Pharmaceuticals, Inc.$263
  • AbbVie$145
  • Amgen$118
  • Alcon$102
  • Sight Sciences, Inc.$79
  • plus $384 from 10 others

What the payments were for

  • Food & beverage$1,390100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,390 in reported general payments places this provider in the 45th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$360,077
Medicare patients
935
Services billed
4,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost416$218,790
VyzultaLatanoprostene Bunod362$158,289
Alphagan PBrimonidine Tartrate150$63,755
Brimonidine Tartrate690$36,505
RestasisCyclosporine28$32,515
CombiganBrimonidine Tartrate/Timolol59$26,366
RhopressaNetarsudil Mesylate57$25,529
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol99$20,432
Dorzolamide-TimololDorzolamide/Timolol/Pf80$17,140
Brinzolamide72$14,716
XiidraLifitegrast15$14,696
Latanoprost1,051$13,525
Timolol MaleateTimolol Maleate/Pf22$12,465
Dorzolamide Hcl592$11,673
SimbrinzaBrinzolamide/Brimonidine Tart43$11,151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Restasis, Combigan$145$341,426653 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$299$172,984377 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$28$29,86868 claims
AlconSimbrinza$102$11,15143 claims
Thea Pharma Inc.Iyuzeh$40$10,80228 claims
NovartisTravatan Z, Ilevro$28$10,49024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Willingboro

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →